Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Erin D. Ellis et al.|JAMA Oncology|2020Cited by 707
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Debasish Tripathy et al.|Journal of Clinical Oncology|2020Cited by 113
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Christina Yau et al.|Nature Communications|2021Cited by 73
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29